吲达帕胺致低钾血症易患性分析  

Clinical Study of the Liability of Indapamide-induced Kaliopenia

作　　者：肖玉芹[1] 周建华[1] 

机构地区：[1]威海市文登中心医院药剂科

出　　处：《世界临床药物》2007年第3期174-176,共3页World Clinical Drug

摘　　要：目的探讨吲达帕胺致低钾血症的易患性。方法分析我院2005年4月-2006年7月服用吲达帕胺的609例原发性高血压患者,将其中75例服药后出现低钾血症者与其余534例未发生低钾血症者进行比较,总结其易患性特点。结果较大剂量用药、老年及合并糖尿病者应用吲达帕胺后易发生低钾血症。结论吲达帕胺致低钾血症具有明显的易患性,合理选择病例可以降低其不良反应的发生率。Objective To investigate the liability of indapamide-induced kaliopenia. Methods 75 of 609 patients with essential hypertension who were administered indapamide developed kaliopenia. Compared these patients with those who did not develop kaliopenia. Result Elderly patients, patients with diabetes and those who were administered large-close indapamide trended to develop kaliopenia. Conclusion Indapamide-induced kaliopenia has evident liability.

关 键 词：吲达帕胺 低钾血症 易患性 

分 类 号：R972.4[医药卫生—药品]